8-K: Liminatus Pharma Completes Business Combination with Iris Acquisition Corp, Trading Commences on Nasdaq

Liminatus Pharma finalizes its merger with Iris Acquisition Corp, marking its debut on the Nasdaq stock market under the ticker symbols LIMN and LIMNW.

Summary

• Iris Acquisition Corp. and Liminatus Pharma have completed their business combination, resulting in Liminatus Pharma, Inc. becoming a publicly traded company.
• The transaction involved the merger of Liminatus Pharma Merger Sub with Liminatus and SPAC Merger Sub with Iris, with Liminatus and Iris surviving as wholly-owned subsidiaries of Iris Parent Holding Corp. (now Liminatus Pharma, Inc.).
• Former Iris stockholders received one share of Liminatus Pharma, Inc. common stock for each share of Iris Class A common stock.
• Public warrants of Iris converted into the right to purchase shares of Liminatus Pharma, Inc. common stock.
• The aggregate consideration paid to the owners of Liminatus was 17.5 million shares of Liminatus Pharma, Inc. common stock, based on a deemed price of $10.00 per share.
• Concurrently with the closing, Liminatus Pharma, Inc. completed a PIPE equity investment, issuing 1,500,000 shares at $10.00 per share, raising $15,000,000.
• Trading of Liminatus Pharma, Inc. common stock and public warrants commenced on the Nasdaq on May 1, 2025, under the symbols LIMN and LIMNW, respectively.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The business combination is complete, and the company is now publicly traded. However, there are risks associated with the company's future success and potential need for additional funding.

Positives

• Liminatus Pharma gains access to public markets and additional capital through the business combination.
• The PIPE equity investment provides $15 million in funding for the company.
• The company's shares and warrants are now trading on the Nasdaq, increasing visibility and potential liquidity.

Negatives

• 59,844 Iris Class A Shares were redeemed for approximately $702,359 from the trust account.
• Certain Liminatus Members will not be able to transfer any shares of ParentCo Common Stock beneficially owned or otherwise held by them for a period that is the earlier of: (a) for one-third of the shares, six months after the Closing Date, for one-third of the shares, twelve months after the Closing Date; and for one-third of the shares, twenty-four months after the Closing Date; (b) the date on which the closing price of the ParentCo Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) for any 20 trading days within any 30-trading day period; or (c) the date on which ParentCo completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of ParentCos stockholders having the right to exchange their shares of ParentCo common stock for cash, securities or other property.

Risks

• The company's future success depends on its ability to develop and commercialize its product candidates.
• The company may require additional funding in the future to support its operations.
• The market price of the company's stock may be volatile.

Future Outlook

The company intends to devote most of the net proceeds from the Business Combination to clinical development of its product candidates, repaying its debt, its public company compliance costs and certain of the milestone payments under the CAR-T License and the Vaccine License agreements, if any.

Industry Context

The announcement reflects the ongoing trend of SPAC mergers as a route for private companies, particularly in the biotech sector, to access public markets and secure funding for research and development.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards as it is a merger announcement and not a financial result.
• Comparable companies that have recently completed SPAC mergers in the biotech space include companies such as 23andMe which merged with VG Acquisition Corp.
• These companies often use the funds raised to advance clinical trials and expand their product pipelines.

Management Changes

Corporate Governance

Legal Proceedings

• From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
• The Company is not a party to any material legal proceedings and is not aware of any material pending or threatened claims.

Stakeholder Impact

• Shareholders: Existing Iris shareholders now hold shares in Liminatus Pharma, Inc., with potential for value appreciation.
• Employees: The merger may bring new opportunities and challenges for employees of both companies.
• Customers: The merger may lead to new product offerings or improved services.
• Suppliers: The merger may impact existing supplier relationships.
• Creditors: The merger may affect the creditworthiness of the combined company.

Next Steps

• Clinical development of product candidates.
• Repaying debt.
• Managing public company compliance costs.
• Potentially making milestone payments under the CAR-T and Vaccine License agreements.

Key Dates

Keywords

Business Combination, Liminatus Pharma, Iris Acquisition Corp, Merger, Nasdaq, PIPE Investment, Public Listing, Warrants, SPAC